Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Tuberculosis

  Free Subscription


30.03.2020

1 Am J Respir Crit Care Med
1 Antimicrob Agents Chemother
3 Eur Respir J
3 Lancet
2 Lancet Respir Med
2 N Engl J Med
5 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. OH JY, Min KH, Lee SY, Shim JJ, et al
    Invasive Endobronchial Mycobacterium kansasii Infection.
    Am J Respir Crit Care Med. 2019;200:e143-e144.
    PubMed        


    Antimicrob Agents Chemother

  2. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
    Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"
    Antimicrob Agents Chemother. 2020;64.
    PubMed        


    Eur Respir J

  3. CEGIELSKI JP, Nahid P, Sotgiu G
    The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2020;55.
    PubMed        

  4. GEBRESELASSIE N, Hutubessy R, Vekemans J, den Boon S, et al
    The case for assessing the full value of new tuberculosis vaccines.
    Eur Respir J. 2020;55.
    PubMed        

  5. FIEBIG L, Beyene N, Burny R, Fast CD, et al
    From pests to tests: training rats to diagnose tuberculosis.
    Eur Respir J. 2020;55.
    PubMed        


    Lancet

  6. SAHU S, Ditiu L, Lawson L, Ntoumi F, et al
    UN General Assembly tuberculosis targets: are we on track?
    Lancet. 2020;395:928-930.
    PubMed        

  7. CAMPBELL JR, Bastos ML
    No time to waste: preventing tuberculosis in children.
    Lancet. 2020;395:924-926.
    PubMed        

  8. MARTINEZ L, Cords O, Horsburgh CR, Andrews JR, et al
    The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis.
    Lancet. 2020;395:973-984.
    PubMed         Abstract available


    Lancet Respir Med

  9. LAN Z, Ahmad N, Baghaei P, Barkane L, et al
    Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    Lancet Respir Med. 2020 Mar 16. pii: S2213-2600(20)30047.
    PubMed         Abstract available

  10. VARIAVA E, Martinson N, Nabeemah F
    Evolving therapies for rifampicin-resistant tuberculosis: balancing efficacy and toxicity.
    Lancet Respir Med. 2020 Mar 16. pii: S2213-2600(20)30038.
    PubMed        


    N Engl J Med

  11. GUPTA A, Montepiedra G, Theron G
    HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply.
    N Engl J Med. 2020;382:1184-1185.
    PubMed        

  12. TIENDREBEOGO T, Anglaret X, Becquet R
    HIV, Pregnancy, and Isoniazid Preventive Therapy.
    N Engl J Med. 2020;382:1184.
    PubMed        


    PLoS One

  13. WU CY, Chiu HY, Tsai TF
    The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.
    PLoS One. 2019;14:e0225112.
    PubMed         Abstract available

  14. BHERING M, Duarte R, Kritski A
    Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016.
    PLoS One. 2019;14:e0218299.
    PubMed         Abstract available

  15. KEBEDE A, Beyene D, Yenew B, Diriba G, et al
    Monitoring quality indicators for the Xpert MTB/RIF molecular assay in Ethiopia.
    PLoS One. 2019;14:e0225205.
    PubMed         Abstract available

  16. SINGH B, Saqib M, Chakraborty A, Bhaskar S, et al
    Lipoarabinomannan from Mycobacterium indicus pranii shows immunostimulatory activity and induces autophagy in macrophages.
    PLoS One. 2019;14:e0224239.
    PubMed         Abstract available

  17. KENDALL EA, Kamoga C, Kitonsa PJ, Nalutaaya A, et al
    Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses.
    PLoS One. 2019;14:e0220251.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: